- Home
- AMZE vs BOLT Comparison
AMZE vs BOLT Comparison
Compare AMZE & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- BOLT
- Stock Information
- Founded
- AMZE 2019
- BOLT 2015
- Country
- AMZE United States
- BOLT United States
- Employees
- AMZE N/A
- BOLT N/A
- Industry
- AMZE Beverages (Production/Distribution)
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- BOLT Health Care
- Exchange
- AMZE Nasdaq
- BOLT Nasdaq
- Market Cap
- AMZE 12.3M
- BOLT 11.5M
- IPO Year
- AMZE 2021
- BOLT 2021
- Fundamental
- Price
- AMZE $0.47
- BOLT $5.14
- Analyst Decision
- AMZE
- BOLT Buy
- Analyst Count
- AMZE 0
- BOLT 4
- Target Price
- AMZE N/A
- BOLT $34.00
- AVG Volume (30 Days)
- AMZE 38.2M
- BOLT 34.2K
- Earning Date
- AMZE 11-14-2025
- BOLT 11-12-2025
- Dividend Yield
- AMZE N/A
- BOLT N/A
- EPS Growth
- AMZE N/A
- BOLT N/A
- EPS
- AMZE N/A
- BOLT N/A
- Revenue
- AMZE $2,245,143.00
- BOLT $5,195,000.00
- Revenue This Year
- AMZE $6,741.66
- BOLT N/A
- Revenue Next Year
- AMZE $100.61
- BOLT N/A
- P/E Ratio
- AMZE N/A
- BOLT N/A
- Revenue Growth
- AMZE 369.95
- BOLT N/A
- 52 Week Low
- AMZE $0.24
- BOLT $4.41
- 52 Week High
- AMZE $19.44
- BOLT $13.00
- Technical
- Relative Strength Index (RSI)
- AMZE 37.43
- BOLT 50.36
- Support Level
- AMZE $0.24
- BOLT $4.66
- Resistance Level
- AMZE $0.38
- BOLT $5.14
- Average True Range (ATR)
- AMZE 0.13
- BOLT 0.28
- MACD
- AMZE 0.07
- BOLT 0.06
- Stochastic Oscillator
- AMZE 36.47
- BOLT 90.41
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.